PrAmoxicillin sodium and potassium clavulanate for injection (AmoxiClav IV) is indicated for the treatment of bacterial infections such as community-acquired pneumonia, sinusitis, urinary tract infections and infections associated with surgical procedures.
AmoxiClav IV is the first combination of these antibiotics available for intravenous administration in Canada, but has been used for more than 35 years in Europe.
This product complements the arsenal of antibiotic treatments available to hospital physicians and can potentially help in the fight against antibiotic resistance.
Sandoz also offers an oral version of AmoxiClav, which can facilitate patient transfer and continuity of care upon the return home from the hospital.
Boucherville, June 11, 2020 - Today, Sandoz Canada Inc. announced the launch of PrAmoxicillin sodium and potassium clavulanate for injection, making Sandoz the only company in Canada to offer this injectable antibiotic, whether innovative or generic.
This combination of amoxicillin sodium and potassium clavulanate is part of the group of antibiotics called penicillins. Amoxicillin destroys bacteria that cause infections by preventing them from making their cell walls, and the clavulanic acid supports it. AmoxiClav IV may serve as an effective alternative to other broad-spectrum antibiotics and established drug resistance.
"We are proud of this launch, which not only makes us the first to offer this antibiotic on the Canadian market, but also represents several positive developments in the field of anti-infective treatments, in terms of choice, therapeutic action, continuity of treatment and ultimately the fight against antibiotic resistance," says Martin Arès, Vice President, Generics and Specialty Products. "With 5.2 million daily doses of first-line intravenous antibiotics administered each year in hospitals¹, AmoxiClav IV provides an attractive additional option for healthcare professionals and clearly demonstrates our commitment to the appropriate use of available antibiotics.”
"AmoxiClav IV, used in hospitals or long-term care homes, speeds up treatment through intravenous administration, and with the existing oral product, patients can now be prescribed the same molecules after being discharged from the hospital, reducing the number of antibiotics used," saysDr. Mauricio Ede, Vice President, Scientific and Medical Affairs, Sandoz Canada. "Another important point to note is that AmoxiClav IV presents a novel offer of intravenous broad spectrum antibiotic on the Canadian market. Both these things combined can potentially help in the fight against existing drug resistance on Canadian market.”
Health Canada authorized the marketing of AmoxiClav IV on January 28. Steps are being taken to have the drug reimbursed in all hospitals. AmoxiClav IV is available as a powder for solution for intravenous injection in three different strengths and in packages of 10 vials.
This press release contains forward-looking statements reagarding, amongst others, potential future revenues from the sale of AmoxiClav IV. You should not place undue reliance on these statements. These forward-looking statements reflect management's current beliefs and expectations regarding future events and involve known and unknown risks and significant uncertainties. Should one or more of these risks or uncertainties materialize, or should any of the underlying assumptions prove incorrect, actual results could differ materially from those set forth in the forward-looking statements. There can be no assurance that AmoxiClav IV will be submitted or approved for other additional indications or labelling in other markets, or at any particular time, nor can it be guaranteed that AmoxiClav IV will be approved by a regulatory body or will be commercially successful in the future. In particular, management's expectations regarding AmoxiClav IV could be affected by a number of factors, including: uncertainties inherent in research and development, including unexpected clinical study results and additional analysis of existing clinical data; unexpected regulatory actions, delays or government regulations in general; the company's ability to obtain or maintain intellectual property protection; general economic and industry conditions; the global trend towards streamlining healthcare costs, including constant pressure regarding pricing; unexpected manufacturing problems, and other risks and factors mentioned in form 20-F filed by Novartis AG with the US Securities and Exchange Commission. Sandoz is providing the information in this press release as of today and does not undertake any obligation to update any forward-looking statements described herein as a result of new information, future events or other circumstances, except as required by law.
Sandoz Canada is a division of Sandoz International GmbH, a world leader in generics and biosimilars and a division of the Swiss multinational Novartis AG. A true leader in its field, Sandoz Canada markets and distributes a wide range of generics, biosimilars and specialty products.